A joint trial of ex-pharmaceutical executive Martin Shkreli and Evan Greebel, his co-defendant in a fraud case and his former lawyer, would present a “serious risk” that Shkreli would not receive a fair trial, a federal judge ruled on Wednesday.
Shkreli, the founder and former CEO of Turing Pharmaceuticals, and Greebel, a former partner with Katten Muchin Rosenman, are accused of working together in a scheme to defraud investors in Retrophin Inc. to pay off investors in two hedge funds that Shkreli also founded, MSMB Capital Management and MSMB Healthcare.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
